S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts

Josefine Bostner1, Elin Karlsson1, Cecilia Bivik Eding2, Gizeh Perez-Tenorio1, Hanna Franzén1, Aelita Konstantinell1, Tommy Fornander3, Bo Nordenskjöld1 and Olle Stål1

1Department of Clinical and Experimental Medicine, Department of Oncology 2Department of Clinical and Experimental Medicine, Division of Dermatology, Linköping University, SE-58185 Linköping, Sweden 3Department of Oncology, Karolinska University Hospital, Karolinska Institute, SE-17176 Stockholm, Sweden

Abstract

Detection of signals in the mammalian target of rapamycin (mTOR) and the estrogen receptor (ER) pathways may be a future clinical tool for the prediction of adjuvant treatment response in primary breast cancer. Using immunohistological staining, we investigated the value of the mTOR targets p70-S6 kinase (S6K) 1 and 2 as biomarkers for tamoxifen benefit in two independent clinical trials comparing adjuvant tamoxifen with no tamoxifen or 5 years versus 2 years of tamoxifen treatment. In addition, the prognostic value of the S6Ks was evaluated. We found that S6K1 correlated with proliferation, HER2 status, and cytoplasmic AKT activity, whereas high protein expression levels of S6K2 and phosphorylated (p) S6K were more common in ER-positive, and low-proliferative tumors with pAKT-s473 localized to the nucleus. Nuclear accumulation of S6K1 was indicative of a reduced tamoxifen effect (hazard ratio (HR): 1.07, 95% CI: 0.53–2.81, P = 0.84), compared with a significant benefit from tamoxifen treatment in patients without tumor S6K1 nuclear accumulation (HR: 0.42, 95% CI: 0.29–0.62, P < 0.00001). Also S6K1 and S6K2 activation, indicated by pS6K-t389 expression, was associated with low benefit from tamoxifen (HR: 0.97, 95% CI: 0.50–1.87, P = 0.92). In addition, high protein expression of S6K1, independent of localization, predicted worse prognosis in a multivariate analysis, P = 0.00041 (cytoplasm), P = 0.016 (nucleus). In conclusion, the mTOR-activated kinases S6K1 and S6K2 interfere with proliferation and response to tamoxifen. Monitoring their activity and intracellular localization may provide biomarkers for breast cancer treatment, allowing the identification of a group of patients less likely to benefit from tamoxifen and thus in need of an alternative or additional targeted treatment.

Key Words

- pS6K
- S6K1
- S6K2
- mTOR
- AKT
- estrogen receptor
- endocrine treatment

Introduction

Breast cancer is the most common malignancy among women, with more than 75% of tumors positive for hormone receptors and thereby possibly responsive to adjuvant endocrine treatment. Active signaling in the phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) cascade is a characterized mechanism
of endocrine resistance, with aberrant stimulation promoting estrogen receptor (ER) α (ESR1) activation and tumor growth, despite estrogen antagonizing- or estrogen restriction treatments (Miller et al. 2011). Inhibition with MABs-binding tyrosine kinase receptors, or mTOR inhibition with rapamycin analogues, has been shown clinically to sensitize tumors to endocrine therapy and prolonging time to progression (Baselga et al. 2009, 2012, Johnston et al. 2009, Bachelot et al. 2012). However, the pathway involves negative feedback regulatory mechanisms, which may provide unwanted activation of signals, such as AKT and ERK1/2, upon inhibition (Soares et al. 2013). Inhibitors targeting signals at more than one level have been promising in vitro and it is probably necessary in many tumors to prevent cells from finding alternative routes to proliferation. The best treatment combination for each tumor or subset of tumors has yet to be discovered, although finding large groups of patients responsive to similar therapy will encourage development of new biomarkers and treatments.

Everolimus (Afinitor) has been recently registered as a treatment for women recurring on endocrine therapy. It is a first-generation mTOR inhibitor, targeting the mTOR complex 1 (mTORC1). Two major downstream targets of mTORC1 are the S6 kinases (S6Ks) 1 and 2. Phosphorylation of these proteins reflects the activity of the mTORC1 (Hara et al. 1997). S6K1 and S6K2 are highly homologous proteins encoded by the RPS6KB1 gene in chromosomal region 17q23, and by the RPS6KB2 gene at 11q13, respectively. The S6Ks share several features, such as their ability to phosphorylate the 40S ribosomal protein S6 and the dependence of an activated mTORC1 for complete activation (Lee-Fruman et al. 1999, Park et al. 2002). The two genes are located in the commonly amplified regions in the genome, associated with poor prognosis in breast cancer (Barlund et al. 2000, Bostner et al. 2007, Perez-Tenorio et al. 2011). Gene expression of RPS6KB1 is upregulated in various cancers (Ip et al. 2011, Sridharan & Basu 2011, Li et al. 2012), and we have observed the prognostic value of RPS6KB2 gene expression in breast cancer (Karlsson et al. 2013). Results of studies have indicated increased protein expression of S6K1 and S6K2 in tumors when compared with normal or benign tissue (Filonenko et al. 2004, Ismail 2012, Li et al. 2012). S6K1 protein overexpression predicted poor prognosis in multiple studies (van der Hage et al. 2004, Perez-Tenorio et al. 2011, Ismail 2012).

Measuring phosphorylated (p) threonine (t) at the amino acid residue 389 of S6k has become a method to evaluate mTORC1 kinase activity in vitro. Castellvi et al. (2006) detected increased pS6K expression in malignant ovarian tumors compared with benign ovarian tumors, and high pS6K expression was associated with worse prognosis in two breast cancer cohorts (Noh et al. 2008, Kim et al. 2011).

S6K1 has been shown to phosphorylate the ER on serine (s) 167, inducing conformational changes in the receptor and making it less responsive to the inhibitory effects of tamoxifen (Yamnik et al. 2009). In addition, RPS6KB1 is a target gene for ER transcription (Maruani et al. 2012). S6K2 has recently been brought to light as a potentially important oncoprotein, with fewer essential roles in normal tissue than S6K1, making it an interesting treatment target (Pardo & Seckl 2013).

To further delineate the treatment-predictive role and prognostic value of the S6Ks, we studied protein expression of S6K1, S6K2, and pS6K-t389 in tumors of patients participating in trials comparing adjuvant tamoxifen with no tamoxifen or 2-year with 5-year tamoxifen treatment.

Material and methods

Patients and tumor samples

This study was designed and presented with regard to the reporting recommendations for tumor marker prognostic studies (REMARK) guidelines (McShane et al. 2006). Ethical approval for cohort 1 was from Karolinska Institute Ethics Board. Ethical approval for cohort 2 was obtained from Linköping University Ethics Board.

Cohort 1 (tamoxifen versus no tamoxifen)

The Stockholm trial included a cohort of breast carcinoma patients with node-negative disease and a tumor size not exceeding 30 mm, randomized to tamoxifen or no adjuvant treatment. Radiotherapy was used for patients receiving breast-conserving therapy. No adjuvant chemotherapy was given to this group of patients. Demographic data and detailed information on the cohort have been previously described (Rutqvist & Johansson 2007, Bostner et al. 2013). Tissue micro arrays (TMAs) with three individual cores were constructed from formalin-fixed paraffin-embedded (FFPE) tumors from 912 patients. ER, progesterone receptor (PgR), HER2, pAkt-s473, pER-s167, p-mTOR status, and mitosis were previously determined (Wrange et al. 1978, Rutqvist & Johansson 2007, Bostner et al. 2013).
Cohort 2 (tamoxifen 5 years versus 2 years)

Tumor tissues of invasive primary breast carcinomas were obtained from a randomized trial of 5 years versus 2 years of adjuvant tamoxifen for postmenopausal early-stage breast cancer conducted by the Swedish Breast Cancer Group during 1983–1991 in five regional cancer centers in Sweden (Swedish Breast Cancer Cooperative Group 1996). The 130 tumors available for this study were represented into two TMA blocks, and patients had been diagnosed in the South-east Sweden region. The ER and PgR status had been determined previously through isoelectric focusing or an enzyme immune assay (Wrange et al. 1978, Fernö et al. 1986). In addition, S-phase fraction and HER2 status were later determined (Ferno¨ et al. 2000, Stål et al. 2000). TMAs with three individual cores were constructed from FFPE tumors and 4 μm sections were used for immunohistochemistry.

Immunostaining

The two patient series were analyzed with the MAB against pS6K-t389 at a concentration of 1:100 (Cell Signaling Technology, Danvers, MA, USA; #9206). The tumors were additionally analyzed with the S6K1 antibody at a concentration of 1:100 (Cell Signaling Technology; #2708). The tumors in cohort 2 were stained with a newly synthesized S6K2 antibody at a concentration of 1:100 (kindly provided by Professor Filonenko) (Savinska et al. 2012). The TMAs of cohort 1 had been previously stained with an alternative S6K2 antibody (Perez-Tenorio et al. 2011).

The PT-link system (Dako, Glostrup, Denmark; PT10126) with the Envision FLEX Target Retrieval Solution, Low pH, was used for deparaffinization, rehydration, and epitope retrieval of the TMAs. The slides were washed in PBS/0.05% Tween-20, subjected to endogenous peroxidase inactivation in 3% hydrogen peroxide, washed in PBS/0.5% BSA, blocked for 10 min in serum-free protein block (Spring Bioscience, Freemont, CA, USA), and incubated with primary antibody in a moisturized chamber at 4°C overnight. On day 2, the slides were washed in PBS/0.5% BSA, incubated with secondary antibody (Dako Cytomation Envision + HRP system; Dako) at room temperature for 30 min, washed, developed in PBS/3,3′-diaminobenzidine hydrochloride (DAB) for 8 min, counterstained with hematoxylin for 1 min, washed, dehydrated in an ethanol series, and mounted with Pertex (HistoLab, Västra Frölunda, Sweden). The images at 20× and 40× magnification were produced with an Olympus BX21 microscope and an Olympus DP70 camera, and whole-slide images of the first cohort p-S6K staining were generated using the ScanScope aT at 200× magnification (Aperio, Vista, CA, USA).

Scoring

Before scoring, the tumors were evaluated for scoring cutoffs appropriate for each stain, with regard to intensity levels and percentage of tumor cells with positive staining, when applicable. Scoring was thereafter conducted by two individual observers, blinded to clinical data. A consensus on the score for each tumor was reached following the individual scoring.

In cohort 1, S6K1 intensity was graded for cytoplasm and nuclei individually as 0 (negative), 1 (weak), 2 (medium), and 3 (strong) (Supplementary Table 1, see section on supplementary data given at the end of this article). Cutoff for positive staining was set at strong intensity. In addition, a positive score for nuclear S6K1 expression being stronger than cytoplasmic S6K1 was generated. In cohort 2, S6K1 and S6K2 were evaluated for cytoplasmic and nuclear intensity 0 (negative), 1 (weak), 2 (medium), and 3 (strong). Cutoff was set at medium intensity as fewer than 10% received the highest score. In cohort 1, pS6K-t389 was graded according to cytoplasmic and nuclear intensity into four groups (negative, weak, medium, and strong), and cutoff was set at strong intensity. In cohort 2, pS6K-t389 expression was evaluated for cytoplasmic intensity 0 (negative), 1 (weak), 2 (medium), and 3 (strong)), and proportion (0 (<1%), 1 (1–25%), 2 (26–75%), and 3 (>75%)). A score was generated by adding intensity and proportion (0–6) and the cutoff was set at score >4 for high expression. No nuclear staining of pS6K-t389 was observed in cohort 2.

Statistical analysis

To compare high and low expression in two groups, the Pearson χ²-test was performed. For rank order of expression levels in four groups, the Spearman’s test was applied. Hazard ratios (HRs) with 95% CI were estimated using the Cox proportional hazards model and the time from diagnosis to any breast cancer recurrence was used as an endpoint. Recurrence-free survival (RFS), defined as time to the first of the following events, local or distant recurrence, or breast cancer-related death was compared with the log-rank test and Kaplan–Meier plots were drawn for visualization. Endocrine-treated patients were excluded from the prognostic analyses of the first cohort.
All tamoxifen treatment prediction analyses were restricted to patients with ER-positive tumors, and in cohort 2 analyses were restricted to starting 2 years after diagnosis to avoid arbitrary differences in the two, up until 2 years, identically treated groups. A P value of <0.05 or <0.01 was considered significant. All statistical analyses of the patient cohorts were performed using Statistica 10 software.

Cell culture

The cell line ZR751 (Engel et al. 1978) (ATCC, Manassas, VA, USA; LGC standards, Teddington, Middlesex, UK) was cultured in Optimem without phenol red (Gibco, Life Technologies), supplemented with 4% heat-inactivated fetal bovine serum (Gibco) at 37 °C, 5% CO₂. Cell authentication was done at ATCC using Short-Tandem Repeat Profiling analysis. All experiments were conducted with cells in the exponential growth phase and cell passage number was kept low.

siRNA knockdown

The cells were transfected with siRNA using the Nucleo- factor Kit V with the Amaxa nucleofection system (Lonza, Basel, Switzerland). Briefly, cells were detached, resuspended in 100 μl nucleofector solution with 300 nM siRNA (Silencer Negative Control No. 1; AM4611, S6K1; 110802 and s12284, and S6K2; 471, Ambion by Life Technologies), transferred to cuvettes and transfected in an Amaxa Biosystems Nucleofector II, program P20. The cells were transferred to cell culture media, counted using a Countess Automated Cell Counter (Life Technologies), and seeded at 100 000 cells/ml. After 24 h, cell culture media was changed.

Western blotting analysis

For protein preparation, cells were rinsed in ice-cold PBS, lysed in RIPA buffer, containing 150 mM NaCl, 2% Triton, 0.1% SDS, 50 mM Tris pH 8.0, Complete Mini Protease Inhibitor Cocktail (1836153; Roche), PhosSTOP phosphatase inhibitor cocktail (Roche Pharma), and phosphatase inhibitor cocktail 2 and 3 (P5726 and P0044, Sigma–Aldrich). The cell lysates were incubated on ice for 30 min and centrifuged at 20 800 g. Protein concentration of the supernatants was determined by the colorimetric BCA Protein Assay (Thermo Scientific Pierce, Rockford, IL, USA) and the lysates were stored at −70°C. The samples containing 15 μg protein were denaturated with Laemmli sample buffer (Bio-Rad), β-mercaptoethanol (Bio-Rad), and heating at 95 °C for 5 min, separated on mini-PROTEAN TGX precast gels, 4–15% (Bio-Rad) at 90 V for 15 min and 150 V for 45 min. Separated proteins were transferred onto a PVDF membrane in a Trans-Blot Turbo system (Bio-Rad), program Mixed-MW kDa, for 7 min. The membranes were blocked according to the specification of the primary antibody before incubation with primary antibodies in a blocking buffer overnight at 4 °C. The membranes were washed in Tris (2.5 mM)–Glycine (19.2 mM)–SDS (0.01%) (Bio-Rad) with 0.1% Tween-20, and incubated for 1 h at room temperature with secondary antibodies. The protein bands were visualized using an Amersham ECL Prime Western Blot detection system (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK) and a charge-coupled camera with the software Image Reader LAS-1000 Pro v.2.6 for detection of chemiluminescent signals (Fujifilm LAS-1000, Stockholm, Sweden). The antibodies used for western blotting were S6K1, pS6K-t389, pAkt-s473 (Cell Signaling Technology), S6K2 (kindly provided by Professor Filonenko) (Savinska et al. 2012), and a GAPDH antibody (rabbit monoclonal; Epitomics, Cambridge, UK; #5632-1) was used as internal control. The ladder MagicMark XP Western Protein Standard was used for molecular weight estimations (Life Technologies).

Fixation and paraffin embedding of cells

The cells at 80% confluence were washed in PBS, dissociated from the surface with Tryple express (Life Technologies) for 5 min in 37 °C, and centrifuged at 200 g for 5 min. The cells were washed in PBS and centrifuged again to form a pellet, and fixed with 4% formaldehyde (Sigma–Aldrich) at room temperature for 4 h, visualized with hematoxylin, centrifuged, and dehydrated with an ethanol to xylene gradient overnight. The cell pellet was paraffin embedded at 56°C for 4 h by the addition of new paraffin every hour. The embedded cells were cut in 3 μm sections using a rotation microtome (Microm International GmbH, Waldorf, Germany).

λ-phosphatase assay

Phosphorylation specificity of the pS6K-t389 antibody was determined by dephosphorylation of proteins in heregulin β1 (ImmuNoTools, Friesoythe, Germany, 0.1 μM) (HRG)-treated FFPE ZR751 breast cancer cells by λ-phosphatase (New England Biolabs, Ipswich, MA, USA). The cells on slides were treated with 1000 U λ-phosphatase or
water (control) for 2 h at 37 °C followed by immunohistochemical staining according to the protocol used for the pS6K-t389 antibody.

Results

Immunohistochemical staining of tumors

S6K proteins and phosphorylated kinase expression as potential biomarkers of tamoxifen benefit were analyzed in the two breast cancer cohorts. Distribution of protein expressions and cutoffs in the two cohorts are presented in a Supplementary Table 1 and a mechanistic scheme of the signaling pathways with treatment predictive and prognostic results are presented in Supplementary Figure 1, see section on supplementary data given at the end of this article. Successful staining for S6K1 was found in 849 tumors (cohort 1) and in 130 tumors (cohort 2), and detection of pS6K was possible in 807 tumors (cohort 1) and in 130 tumors (cohort 2).

S6K1 and S6K2 correlate with separate tumor characteristics

In cohort 1, pS6K was highly correlated with both high S6K1 and high S6K2 expression, supporting the antibody selectivity found in vitro toward the two homologs also in FFPE breast tissue (Table 1). In contrast, S6K1 and S6K2 were not significantly co-expressed. Nuclear pS6K correlated well with ER positivity (P<0.001), as did nuclear S6K2 in the two sets, whereas high S6K1 expression was connected with HER2 positivity (Tables 1 and 2).

The AKT protein is central in the PI3K/mTOR-pathway, with its activity being regulated upstream and downstream of the S6Ks. AKT stimulates S6K through mTORC1, and mTORC1 or S6K1 repression commonly results in AKT activation through the release of S6K1 inhibition of the IGF1 receptor regulator IRS1 (Um et al. 2004, Tabernero et al. 2008). A connection between active expression of AKT (pAKT-s473) and all analyzed S6K variants was evident in the first set, with strongest correlations detected when proteins were expressed in the same location: cytoplasm and nucleus respectively (Table 1). We detected strong coexpression of pAKT and pS6K in the nucleus and of pAKT and S6K2 in the nucleus. A pAKT correlation with S6K1 was observed in the cytoplasm. S6K1 and AKT are both known to phosphorylate the ER on serine 167. pS6K correlated well with pER-s167 in the cytoplasm and in the nucleus. pAKT and pER-s167 were strongly associated (P<0.00001), as previously shown in cohort 1 (Bostner et al. 2013). The Spearman rank order test was applied for p-mTOR versus nuclear pS6K (P=0.0002) and for p-mTOR versus nuclear S6K2 (P=0.00002).

We found high nuclear pS6K and high nuclear S6K2 to correlate significantly with small tumor size, but no obvious relationship between S6K1 and tumor size in the first set (Table 1). In the second set the pS6K cytoplasmic expression was correlated with large size of tumors (Table 2). Results of a previous study indicated that overexpression of S6K2 but not S6K1 was important for cell proliferation in HEK293 cells (Goh et al. 2010). Proliferation in our two sets was represented by mitosis in the first set, and S-phase fraction in the second set (Tables 1 and 2). High levels of S6K1 expression indicated increased proliferation, while high levels of nuclear pS6K and S6K2 indicated reduced proliferation in the first set. In the second set, no significant correlations with proliferation were observed; however, a tendency toward increased proliferation was detected with high cytoplasmic S6K1, consistent with results from the first set.

High nuclear S6K1 and high pS6K predict groups that do not benefit from tamoxifen

Up to one-third of the tumors showed a distinct pattern of S6K1 nuclear staining with weaker cytoplasmic staining. A significant tamoxifen benefit was observed in cohort 1 for patients whose tumors did not show the S6K1 nuclear pattern (P<0.00001) (Fig. 1A). The benefit was not evident in patients with tumors showing nuclear dominance of S6K1 (Fig. 1B), and the difference in treatment efficacy between the groups was significant (Table 3). Similarly, patients in cohort 2 with tumors not showing the S6K1 nuclear pattern tended to benefit from prolonged tamoxifen therapy (Fig. 1C and D). No significant treatment-predictive role was identified for S6K2 alone in the two sets (Perez-Tenorio et al. 2011). The role of nuclear S6K2 seemed dependent on the PgR status, showing a loss of treatment response when tumors expressed high levels of nuclear S6K2 and no PgR.

High levels of expression of pS6K in the cytoplasm and nucleus simultaneously resulted in reduced response to tamoxifen compared with low expression in one or both compartments in the first set (Fig. 2A, B and Table 3). In the second set, a trend towards benefit from longer treatment was observed with low pS6K expression (Fig. 2C and D). With a high pS6K expression in the cytoplasm, the potential benefit from longer tamoxifen treatment disappeared.
### Table 1  
Cohort 1: clinicopathological characteristics and pathway-related phosphoprotein expression in correlation with activated pS6K-t389 (pS6K) and total S6Ks in cytoplasm (c) and in nuclear (n) compartments of tumors from postmenopausal breast cancer patients

|          | pS6Kc n (%) | pS6Kn n (%) | S6K1c n (%) | S6K1n n (%) | S6K2c n (%) | S6K2n n (%) |
|----------|-------------|-------------|-------------|-------------|-------------|-------------|
| Low      | High        | P           | Low         | High        | Low         | High        |
| No tamoxifen | 318 (80)   | 79 (20)     | 248 (63)    | 148 (37)    | 377 (90)    | 41 (10)     |
| Tamoxifen | 326 (80)    | 84 (20)     | 236 (62)    | 154 (38)    | 362 (94)    | 69 (16)     |
| Size < 20 mm | 485 (79)   | 126 (21)    | 357 (59)    | 235 (41)    | 537 (105)   | 68 (11)     |
| Size > 20 mm | 144 (81)    | 34 (19)     | 133 (75)    | 45 (25)     | 156 (85)    | 28 (15)     |
| Mitosis low | 366 (80)    | 94 (20)     | 272 (59)    | 190 (41)    | 412 (87)    | 64 (13)     |
| Mitosis high | 199 (81)    | 43 (19)     | 163 (71)    | 68 (29)     | 189 (80)    | 48 (20)     |
| ER−       | 134 (77)    | 39 (23)     | 126 (79)    | 48 (21)     | 162 (89)    | 21 (11)     |
| ER+       | 495 (81)    | 117 (19)    | 364 (59)    | 248 (41)    | 383 (89)    | 103 (16)    |
| PgR−      | 276 (79)    | 72 (21)     | 230 (66)    | 117 (34)    | 294 (82)    | 66 (18)     |
| PgR+      | 300 (80)    | 70 (20)     | 225 (61)    | 146 (39)    | 330 (86)    | 55 (14)     |
| HER2−     | 528 (80)    | 130 (20)    | 419 (64)    | 239 (36)    | 595 (86)    | 93 (14)     |
| HER2+     | 70 (80)     | 18 (20)     | 50 (57)     | 37 (43)     | 68 (73)     | 23 (25)     |
| pAkt c low | 265 (86)    | 44 (14)     | 217 (70)    | 92 (30)     | 302 (93)    | 22 (7)      |
| pAkt c high | 360 (76)    | 112 (24)    | 269 (57)    | 202 (43)    | 417 (80)    | 62 (13)     |
| pAkt n low | 470 (84)    | 89 (16)     | 396 (71)    | 162 (29)    | 518 (90)    | 60 (10)     |
| pAkt n high | 155 (70)    | 60 (30)     | 90 (41)     | 132 (59)    | 201 (89)    | 24 (11)     |
| pER−167 low | 529 (83)    | 108 (17)    | 442 (70)    | 194 (31)    | 595 (85)    | 60 (10)     |
| pER−167 high | 115 (68)    | 54 (32)     | 62 (37)     | 107 (63)    | 156 (89)    | 20 (11)     |
| p53 c low  | 436 (68)    | 207 (32)    | 582 (91)    | 58 (9)      | 548 (84)    | 92 (14)     |
| p53 c high | 68 (42)     | 95 (58)     | 113 (93)    | 28 (17)     | 124 (77)    | 37 (23)     |
| pS6K c low | 254 (85)    | 46 (15)     | 229 (76)    | 71 (24)     | 301 (79)    | 82 (21)     |
| pS6K n low | 155 (70)    | 60 (30)     | 90 (41)     | 132 (59)    | 201 (89)    | 24 (11)     |

Pearson χ²P values < 0.01 were considered to be statistically significant.
S6K1 expression indicates worse prognosis

High S6K1 protein expression, independent of localization, predicted a poor prognosis in the tamoxifen-untreated subgroup (Fig. 3A and B). This was also true in multivariate analysis, adjusting for tumor size, grade, HER2-, ER-, and PgR status ($P = 0.00041$ for S6K1 in the cytoplasm and $P = 0.016$ for S6K1 in the nucleus). The tamoxifen-treated group did not differ in recurrence rate in relation to cytoplasmic S6K1 expression (data not shown). The second cohort did not include tamoxifen-untreated patients and no significant relationship between recurrence rate and S6K1 expression was observed in the analysis of all patients (Fig. 3C). S6K2 amplification has previously been shown to be a marker of worse prognosis in stage II breast cancer (Perez-Tenorio et al. 2011). Strong S6K2 expression did not associate with prognosis in either of the two cohorts. Thus, pS6K did not qualify as a prognostic marker irrespective of intracellular localization, cutoff, HER2 status, or cohort. A tendency towards improved breast cancer survival was found for high levels of pS6K in the nucleus (HR: 0.72, 95% CI: 0.44–1.17, $P = 0.18$).

In vitro validation shows antibody specificity

The ER-positive breast cancer cell line ZR751 was transfected with siRNA to knockdown the S6K1 and S6K2 mRNAs, separately and in combination. Results of western blotting indicated almost complete knockdown of proteins at 72 h, indicating an efficient transfection and specific target detection with the antibodies (Fig. 4). The S6K2 antibody showed a weak non-specific band slightly larger than the specific band, which was not S6K1 as the band remained after S6K1 knockdown. The pS6K-t389 (pS6K) antibody detected both pS6K1 and pS6K2 as the band remained after S6K1 knockdown. The pS6K-t389 band was also detected after S6K2 knockdown, indicating an efficient knockdown of S6K2 mRNA. In combination, the specific bands of the two phosphorylated homologs were distinguishable by western blotting. AKT was additionally phosphorylated after S6K1 knockdown. This was not evident after S6K2 knockdown.

FFPE cells treated with HRG showed increased expression of pS6K compared with control, indicating the antibody's validity on FFPE tissue (Supplementary Figure 2A, B, and C, see section on supplementary data given at the end of this article). The phosphorylation specificity of the p-S6K antibody was validated with FFPE cells treated with $\lambda$-phosphatase.

Table 2  Cohort 2: clinicopathological characteristics in correlation with active pS6K-t389 (pS6K) and total S6Ks in cytoplasm (c) and in nucleus (n) in tumors from postmenopausal breast cancer patients

|                | pS6K c (%) |             |       | S6K1 c (%) |             |       | S6K1 n (%) |             |       | S6K2 c (%) |             |       | S6K2 n (%) |             |
|----------------|------------|-------------|-------|------------|-------------|-------|------------|-------------|-------|------------|-------------|-------|------------|-------------|
|                | Low        | High        | $P$   | Low        | High        | $P$   | Low        | High        | $P$   | Low        | High        | $P$   | Low        | High        | $P$   |
| Tamoxifen 2 years | 45 (71) | 18 (29) |       | 46 (73) | 17 (27) | 0.7   | 46 (52) | 43 (48) | 0.3   | 43 (80) | 11 (20) | 0.7   | 32 (45) | 39 (55) | 0.7   |
| Tamoxifen 5 years | 50 (75) | 17 (25) |       | 46 (69) | 21 (31) | 0.6   | 17 (41) | 24 (59) | 0.3   | 51 (82) | 11 (18) | 0.7   | 22 (49) | 23 (51) | 0.7   |
| Size < 20 mm    | 56 (65) | 30 (35) | 0.004 | 34 (79) | 9 (21)  |       | 10 (24) | 31 (76) | 0.2   | 62 (82) | 14 (18) | 0.8   | 34 (62) | 21 (38) | 0.2   |
| Size > 20 mm    | 48 (72) | 19 (28) |       | 58 (67) | 29 (33) | 0.1   | 47 (70) | 20 (30) |       | 47 (77) | 14 (23) | 0.2   | 27 (73) | 10 (27) | 0.3   |
| S phase low     | 27 (79) | 7 (21)  | 0.4    | 18 (53) | 16 (47) | 0.06  | 21 (60) | 14 (40) | 0.3   | 25 (81) | 6 (19)  | 0.7   | 22 (81) | 5 (19)  | 0.3   |
| S phase high    | 19 (63) | 11 (37) |       | 25 (83) | 5 (17)  |       | 24 (27) | 65 (73) |       | 22 (81) | 5 (19)  | 0.7   | 22 (81) | 49 (69) |       |
| ER −           | 76 (76) | 24 (24) | 0.2    | 67 (67) | 33 (33) | 0.08  | 6 (15)  | 35 (85) | 0.1   | 72 (81) | 17 (19) | 0.9   | 5 (11)  | 40 (89) | 0.01  |
| ER +           | 31 (58) | 22 (42) |       | 39 (72) | 15 (28) |       | 37 (42) | 52 (58) |       | 40 (82) | 9 (18)  |       | 32 (45) | 39 (55) |       |
| PgR −          | 64 (83) | 13 (17) | 0.002  | 53 (70) | 23 (30) | 0.8   | 17 (41) | 24 (59) | 1.0   | 54 (81) | 13 (19) | 0.9   | 17 (38) | 28 (62) | 0.4   |
| PgR +          | 79 (73) | 29 (27) |       | 79 (72) | 30 (28) |       | 75 (89) | 9 (11)  |       | 76 (78) | 21 (22) |       | 63 (91) | 6 (9)   | 0.2   |
| HER2 −         | 10 (77) | 3 (23)  | 0.8    | 8 (67)  | 4 (33)  | 0.7   | 34 (92) | 3 (8)   | 0.7   | 10 (91) | 1 (9)   | 0.3   | 34 (87) | 5 (13)  | 0.5   |
| HER2 +         | 65 (69) | 29 (31) |       | 30 (73) | 11 (27) | 1.0   | 71 (85) | 13 (15) |       | 54 (77) | 16 (23) |       | 30 (27) | 33 (67) | 0.2   |
| pS6K low       | 26 (74) | 9 (26)  | 0.6    | 64 (73) | 24 (27) |       | 22 (71) | 9 (29)  | 0.1   | 22 (71) | 9 (29)  |       | 22 (71) | 9 (29)  | 0.1   |
| pS6K high      | 27 (74) | 9 (26)  | 0.6    | 64 (73) | 24 (27) |       | 22 (71) | 9 (29)  | 0.1   | 22 (71) | 9 (29)  |       | 22 (71) | 9 (29)  | 0.1   |
resulted in a decreased epitope binding of the antibody. The S6K1 antibody showed high specificity on FFPE cells, with almost complete loss of staining after S6K1 siRNA transfection (Supplementary Figure 2D and E).

Discussion

Signaling of the S6ks downstream of mTORC1 was retrospectively evaluated in two randomized sets of breast cancer patients. In this study, we have demonstrated S6K protein expression, activity, and location to be the useful markers for prediction of response to endocrine treatment, and for prognosis.

Resistance to endocrine treatments remains the reality for a large group of patients with recurring breast cancer, and validated biomarkers for treatment prediction in primary tumors are scarce besides ER and PgR status. Aberrant P13K/mTOR-signaling is a highlighted cascade in endocrine therapy resistance, leading to maintained proliferation despite inhibition of hormonal-stimulatory effects. Therefore, we examined S6K1 and S6K2 as markers for activity in the pathway. The protein pEr-s167, a downstream target for phosphorylation by AKT, S6K1, and RSK, has been shown previously to increase ER transcriptional activity, and consequently affect the proliferation rate (Yamnik & Holz 2010). The mTORC1 inhibitor rapamycin as well as S6K1 knockdown retained osteosarcoma cells in G1 phase (Fingar et al. 2004), and S6K1 indirectly induced proliferation through ER stimulation in epithelial cells (Yamnik et al. 2009). A mutant active S6K2 in immune cells increased proliferation (Cruz et al. 2005), and in embryonic cells from S6kJ/2-knockout mice mild proliferation defects were observed (Kawasome et al. 1998, Pendle et al. 2004). Results of several studies have suggested diverse roles of the S6k isoforms in cell-cycle progression (Lane et al. 1993, Reinhard et al. 1994, Fingar et al. 2004, Boyer et al. 2008). Consequently, the involvement of the S6ks in proliferation is established in a variety of cells and systems. The common and separate roles of the two homologues for breast cancer patients are yet to be elucidated.

This is the first study to our knowledge to show that a dominant pattern of nuclear S6K1 is associated with reduced benefit from tamoxifen in breast cancer patients,

![Figure 1](http://erc.endocrinology-journals.org)  
Figure 1  
Benefit of tamoxifen in ER-positive patients grouped according to location of S6K1 expression. (A versus B) S6K1 accumulation in the nucleus predicted loss of tamoxifen benefit when compared with endocrine-untreated patients in cohort 1 (n=641), P value for interaction was 0.025, and (C versus D) a reduction in the benefit from 5 years of tamoxifen treatment compared with 2 years of treatment in cohort 2 (n=91), P value for interaction was 0.25.

Table 3  
Cox proportional hazard analysis of the benefit from tamoxifen in patients with ER-positive tumors in relation to S6K1 nuclear (n) and cytoplasmic (c) location, and phosphorylated S6K-t389 (pS6K) expression

| Figure | Cohort | HR | 95% CI | P (cox) | P (interact) |
|--------|--------|----|--------|---------|-------------|
| S6K1 n< c | 1A | 1 | 0.42 | 0.29–0.62 | 0.000007 | 0.025 | 0.016 |
| S6K1 n> c | 1B | 1 | 1.07 | 0.53–2.18 | 0.84 | 0.25 | 0.25 |
| S6K1 n< c | 1C | 2 | 0.48 | 0.19–1.20 | 0.12 | 0.25 | 0.25 |
| S6K1 n> c | 1D | 2 | 1.29 | 0.35–4.82 | 0.70 | 0.25 | 0.25 |
| pS6K low | 2A | 1 | 0.44 | 0.30–0.65 | 0.000037 | 0.060 | 0.040 |
| pS6K high | 2B | 1 | 0.97 | 0.50–1.87 | 0.92 | 0.060 | 0.040 |
| pS6K low | 2C | 2 | 0.47 | 0.20–1.11 | 0.085 | 0.13 | 0.13 |
| pS6K high | 2D | 2 | 1.69 | 0.38–7.57 | 0.50 | 0.13 | 0.13 |
indicating that nuclear accumulation of S6K1 in primary biopsies may serve as a potential target to prevent treatment resistance. In addition, cytoplasmic and nuclear overexpression of S6K1 significantly indicated worse prognosis independent of HER2 gene amplification, consistent with results of previous studies on S6K1 protein expression and RPS6KB1 gene amplification and expression (van der Hage et al. 2004, Perez-Tenorio et al. 2011). The S6K1 antibody demonstrated high specificity and could serve as a clinical biomarker.

Overactivated S6K has been suggested an upcoming prognostic and treatment predictive marker in ER-positive breast cancer (Noh et al. 2008, Kim et al. 2011, Beelen et al. 2014). Here, we did not detect worse prognosis with high activity of the S6Ks, instead a somewhat improved prognosis was observed in the tamoxifen-untreated subset of patients when pS6K was highly expressed in the nucleus. Recently, Beelen et al. (2014) have shown an improved prognosis with high levels of pS6K expression in the cytoplasm. It has been suggested that the p31 short isoform of S6K1 is the primary oncogenic protein in the S6K family (Rosner & Hengstschlager 2011). The pS6K-t389 antibody did not detect this short isoform, which could be an explanation as to why its prognostic value was not seen in our study. Regarding the treatment-predictive value of pS6K-t389, we found high simultaneous expression in cytoplasmic and nuclear compartments to indicate loss of benefit from tamoxifen in the two cohorts. These results highlight pS6K as one of the potential markers in the PI3K/ER crosstalk interfering with response to tamoxifen treatment. The antibody showed high specificity on western blots as well as on FFPE cells. Staining with the phosphorylation-specific antibody was evaluated in the two cohorts, separately. Slightly different staining patterns were observed between the cohorts, with nuclear staining only in the first set and variations in staining intensity, although the antibody concentration and method were identical. Therefore, we recommend the phosphorylation-specific S6K antibody to be further investigated before it is taken into consideration for clinical use. Instead, we suggest that this antibody may serve as a validated marker in cohort studies for further evaluation of mTOR inhibition and endocrine treatment response.

S6K2 was found in protein complexes by the centromere in the nuclear membrane (Rossi et al. 2007), and the results of an in silico study indicated domains of the S6K2 to connect to chromatin (Ismael et al. 2014). In vitro data indicated that S6K2, not S6K1 or AKT, binds histone 3 and that this was dependent on the C-terminal nuclear localization signal in the S6K2 protein. On the other hand, growth factor stimulation of S6K2 induced phosphorylation of the C-terminal nuclear localizing signal, retaining active S6K2 in the cytoplasm (Valovka et al. 2003). This indicates that S6K2 has active roles in the nuclear and in the cytoplasmic compartment, with possible involvement in proliferation. In contrast, mTOR-dependent growth factor stimulation led to nuclear localization of S6K1 in G1 phase, indicating that a high level of expression of S6K1 in the nucleus is a marker of extracellular growth stimulation (Rosner & Hengstschlager 2011). The S6Ks proliferative roles may also act through S6 in concert with 4EBP1, and consequently through translational upregulation of the key G1-to-S phase transition regulator, cyclin D1 (Averous et al. 2008).

We observed a strong correlation of S6K1 with markers of high proliferation, and S6K2 correlation with markers of low proliferation. In contrast, Lyzogubov et al. (2005) reported that S6K2, not S6K1, correlated with the proliferation markers Ki67 and proliferating cell nuclear antigen (PCNA). We found that S6K1 correlated with HER2-positive tumors and S6K2 correlated with ER-positive status. This is probably in part a consequence of co-amplification, as RPS6KB1 is located in the 17q23.
chromosomal region close to the \textit{HER2} gene, and \textit{RPS6KB2} is located to 11q13 close to the \textit{CCND1} gene coding for the cyclin D1 protein, an amplicon strongly connected with \textit{ER} expression, reported in this study and others (Bostner et al. 2007, Aaltonen et al. 2009). The opposing correlations of the two S6Ks with proliferation markers may come from their strong connections with \textit{HER2} and \textit{ER}, respectively, with \textit{HER2} positivity being associated with high proliferation and \textit{ER} with low proliferation. However, the prognostic value of S6K1 overexpression found in this study was independent of \textit{HER2} status.

In glioblastoma, pS6K and pS6 correlated with AKT activation, supporting our findings (Riemenschneider et al. 2006). High levels of expression of pAKT in this study correlated with pS6K in the cytoplasm, mainly S6K1, and in the nucleus, mainly S6K2. However, knockdown of S6K1, but not S6K2, increased the active form of AKT. Inhibition of S6K with rapamycin in pancreatic cancer cells upregulated pAKT, and mTORC1/2 inhibition abrogated the AKT phosphorylation, thus instead the MAPK pathway was activated (Soares et al. 2013). Metformin, on the other hand, inhibited mTOR without the regulatory feedback effects on AKT and MAPK. An effect of mTORC1/2 inhibition was also detected in multiple myeloma cells, with a RAF-dependent activation of ERK (Hoang et al. 2012). This indicates that the regulatory networks connecting the AKT with the S6Ks can be modulated, and with fine-tuned inhibitors the growth stimulation could be restrained. Upregulation of the HER family RTKs is a common resistance response to endocrine treatment in breast cancer. To circumvent this mechanism the RTK/PI3K/mTOR-pathways have been inhibited in various combinations. Axelrod et al. (2014) have recently described S6K as a critical node and a potential single target by describing similar responses to S6K1 inhibition alone as to double-targeting RTKs and PI3K/mTOR. We

Figure 3
S6K1 protein expression as a prognostic marker in endocrine-untreated patients. (A) High S6K1 cytoplasmic (n=418) and (B) nuclear expression indicated a significantly worse prognosis in cohort 1 (n=418). (C) S6K1 cytoplasmic and nuclear expression in all tumors from cohort 2 had no significant prognostic value, although the trend mirrored the results from cohort 1 (n=130).

Figure 4
Antibodies showed specific epitope recognition in western blotting. S6K1 and S6K2 protein was downregulated upon siRNA transfection of ZR75-1 breast cancer cells. The pS6K-t389 antibody detected phosphorylated residues of S6K1 (70 and 85 kDa) and of S6K2 (60 kDa). AKT phosphorylation was induced by S6K1 knockdown. Removal of S6K2 did not induce AKT phosphorylation. GAPDH was used as a control for equal protein loading. The figure is a representative of three independent experiments.
suggest that detection of S6K1 and pS6K1/2 could be used to identify patients with de novo resistance to tamoxifen, thus in need of additional targeted inhibition.

Phosphorylated epitopes are known to be unstable and highly dependent on fixation methods, which could be one reason that yet none has reached clinical use for prognostic or treatment predictive purposes. Therefore, we sought to thoroughly validate a well-known antibody targeting a potentially important site within the PI3K/mTOR cascade; the pS6K-t389 antibody from Cell Signaling Technology. Results from western blot analyses indicate that the antibody detected phosphorylated residues seen as three separated bands, interpreted as the two isoforms of S6K1, p70 and p85, and a single band from the two S6K2 isoforms, p54 and p56. The corresponding bands disappeared in an expected pattern upon knockdown of the two proteins, separately. For clinical use, an antibody should be validated on fixed tissue. Therefore, we used formalin-fixed and paraffin-embedded cells after stimulation with HRG. We observed increased staining after HRG stimulation and the results of a phosphatase assay indicated phosphorylation specificity of the antibody. To test the S6K1 antibody, we induced down-regulation of protein using siRNA transfection and showed high specificity of the S6K1 antibody on formalin-fixed and paraffin-embedded cells.

In conclusion, it is a matter of urgency to identify subgroups of breast cancer patients who fail to respond to endocrine treatment. Biomarkers predicting the response to endocrine treatment and identification of patients likely to benefit from mTOR inhibition will improve survival rates and prolong time to recurrence. In this study, we provide data on the involvement of S6K in effects of tamoxifen treatment and resistance, with S6K1 protein localization as a potential clinical biomarker. Patients with tumors showing high expression of the biomarker may respond well to an additional targeted treatment along with endocrine treatment in the neoadjuvant or adjuvant setting, as this may reduce recurrence of endocrine-treated breast cancer.

**Supplementary data**

This is linked to the online version of the paper at http://dx.doi.org/10.1530/ERC-14-0513.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

Financial support was obtained from the Swedish Cancer Society, the Swedish Research Council, the Östergötland County Council, and the Lions Research Fund.

**Author contribution statement**

J Bostner, E Karlsson, and O Stål were involved in establishment of the project; J Bostner, E Karlsson, C B Eding, G Perez-Tenorio, and O Stål were involved in scientific directions of the project; T Forander, and B Nordenskjöld contributed to the materials and clinical data; J Bostner, E Karlsson, H Franzen, and A Konstantinell performed immunohistochemical analysis and scoring; J Bostner, E Karlsson, C B Eding, G Perez-Tenorio, and O Stål performed statistical analysis and data evaluation; J Bostner, C B Eding, and H Franzen performed in vitro antibody validation procedures; and all authors have read and approved the final manuscript.

**Acknowledgements**

The authors express a special thanks to the technicians Birgitta Holmlund and Helén Richard.

**References**

Aaltonen K, Amini RM, Landberg G, Errola H, Aittomäki K, Heikkilä P, Nevanlinna H & Blomqvist C 2009 Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer. Breast Cancer Research and Treatment 113 75–82. (doi:10.1007/s10549-008-9908-5)

Averous J, Fonseca BD & Proud CG 2008 Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 27 1106–1113. (doi:10.1080/02612030802110715)

Axelrod MJ, Gordon V, Mendez RE, Leimgruber SS, Conaway MR, Sharlow ER, Jameson MJ, Gioeli DG & Weber MJ 2014 p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. Cellular Signalling 26 1627–1635. (doi:10.1016/j.cellsig.2014.03.013)

Bachelot T, Bourjot C, Cropert C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Dehbed M, Spaeth D et al. 2012 Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of Clinical Oncology 30 2718–2724. (doi:10.1200/JCO.2011.39.0708)

Barlund M, Forrozan F, Kononen J, Babendorf L, Chen Y, Bittner ML, Toninoto J, Haaf P, Bucher C, Sauter G et al. 2000 Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. Journal of the National Cancer Institute 92 1252–1259. (doi:10.1093/jnci/92.15.1252)

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 27 2630–2637. (doi:10.1200/JCO.2008.18.8391)

Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahnoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F et al. 2012 Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine 366 520–529. (doi:10.1056/NEJMoa1109653)
Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Wesseling J, Muris JJ, Berns EM, Vermorken JB, van Diest PJ et al. 2014 Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. Breast Cancer Research 16:R6.

Bostner J, Ahnstro¨ m Waltersson M, Fornander T, Skoog L, Nordenskjo¨ ld B, & Stål O. 2007 Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26:6997–7005. (doi:10.1038/sj.onc.1210506)

Bostner J, Karlsson E, Pandiyan MJ, Westman H, Skoog L, Fornander T, Nordenskjo¨ ld B & Stål O. 2013 Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit. Breast Cancer Research and Treatment 137:397–406. (doi:10.1007/s10549-012-1276-y)

Boyer D, Quintanilla R & Lee-Frumen KK. 2008 Regulation of catalytic activity of S6 kinase 2 during cell cycle. Molecular and Cellular Biochemistry 307:59–64. (doi:10.1007/s11010-007-9584-5)

Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Basela J & Ramon y Cajal S. 2006 Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107:1801–1811. (doi:10.1002/cncr.22195)

Cruz R, Hedden L, Boyer D, Kharas MG, Fruman DA & Lee-Frumen KK. 2005 S6 kinase 2 potentiates interleukin-3-driven cell proliferation. Journal of Leukocyte Biology 78:1378–1385. (doi:10.1189/jlb.0405252)

Engel LW, Young NA, Tralka TS, Lippman ME, O’Brien SJ & Joyce MJ. 1978 Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Research 38:3352–3364.

Ferri M, Borg A & Sellberg G 1986 Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiologica. Oncology 25:171–175. (doi:10.3109/02841868609633859)

Ferri M, Stål O, Balderorp B, Hatschek T, Kallström AC, Malmström P, Nordenskjo¨ ld B & Ryden S. 2000 Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Research and Treatment 59:69–76. (doi:10.1023/A:1006632424360)

Filonenko VV, Tytarennok R, Azatjan SK, Savinska LO, Gaydar YA, Gout IT, Usenko VS & Lyzogubov VB. 2004 Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors. Experimental Oncology 26:294–299.

Finger DC, Richardson CJ, Tee AR, Cheatham L, Tsou C & Blenis J. 2004 mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Molecular and Cellular Biology 24:290–216. (doi:10.1128/MCB.24.1.200-216.2004)

Goh ET, Pardo OE, Michael N, Niewiarowski A, Totty N, Volkova D, Tsvaneva IR, Seckl OJ & Gout I. 2010 Characterization of S6K2, a novel kinase homologous to S6K1. Molecular and Cellular Biology 30:17065–17076. (doi:10.1074/jbc.M109.078782)

Hoang B, Benavides A, Shi Y, Yang Y, Frost P, Gera J & Lichtenstein A. 2012 The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eif-4E)/RAF pathway and activation is a mechanism of resistance. Journal of Biological Chemistry 287:21796–21805. (doi:10.1074/jbc.M111.304626)

Ip CK, Cheung AN, Ngan HY & Wong AS. 2011 p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene 30:2420–2432. (doi:10.1038/onc.2010.615)

Ismail HM. 2012 Overexpression of S6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients’ survival. Journal of Oncology 2012:146927. (doi:10.1155/2012/146927)

Ismail HM, Hurd PJ, Khalili M, Kouzarides T, Bannister A & Gout I. 2014 S6 kinase 2 is bound to chromatin-nuclear matrix cellular fractions and is able to phosphorylate histone H3 at threonine 45 in vitro and in vivo. Journal of Cellular Biochemistry 115:1048–1062. (doi:10.1002/jcb.24566)

Johnson S, Pippet J, Jr., Pivot X, Lichinitser M, Sadeghi S, Diers V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ et al. 2009 Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology 27:5538–5546. (doi:10.1200/JCO.2009.23.3734)

Karlsson E, Perez-Tenorio G, Amin R, Bostner J, Skoog L, Fornander T, Iggo DC, Nordenskjöld B, Hallbeck AL & Stål O. 2013 The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Research 15:R96. (doi:10.1186/bcr3557)

Kawasome H, Papst P, Webb S, Keller GM, Johnson GL, Gelfand EW & Terada N. 1998 Targeted disruption of p70<sup>65kDa</sup> defines its role in protein synthesis and rapamycin sensitivity. PNAS 95:5033–5038. (doi:10.1073/pnas.95.9.5033)

Kim EK, Kim HA, Koh JS, Kim MS, Kim KI, Lee JH, Moon NM, Ko E & Noh WC. 2011 Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Research and Treatment 126:95–99. (doi:10.1007/s10549-010-1135-z)

Lane HA, Fernandez A, Lamb NJ & Thomas G. 1993 p70<sup>65kDa</sup> function is essential for G1 progression. Nature 363:170–172. (doi:10.1038/363170a0)

Lee-Frumen KK, Kuo CJ, Lippincott J, Terada N & Blenis J. 1999 Characterization of S6K2, a novel kinase homologous to S6K1. Oncogene 18:5108–5114. (doi:10.1038/sj.onc.1202894)

Li PD, Zhang WJ, Zhang MY, Yuan LJ, Cha YL, Ying XF, Wu G & Wang HY. 2012 Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients. Medical Oncology 29:3070–3076. (doi:10.1007/s12032-012-0268-x)

Lyzogubov VB, Khozhaenko Y, Usenko V, Antonjuk S, Ovcharenko G, Tikhonkova I & Filonenko V. 2005 Immunohistochemical analysis of Ki-67, PCNA and S6K1/2 expression in human breast cancer. Experimental Oncology 27:141–144.

Maruani DM, Spiegel TN, Harris EN, Shachter AS, Unger HA, Herrero-González S & Holz MK. 2012 Estrogens regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation. Oncogene 31:5073–5080. (doi:10.1038/onc.2011.657)

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM & Statistics Subcomittee of NC1-EORTC Working Group on Cancer Diagnostics. 2006 Reporting recommendations for tumor marker prognostic studies (REMARK). Breast Cancer Research and Treatment 100:229–231. (doi:10.1007/s10549-006-9242-8)

Miller TW, Balco JM & Arteaga CL. 2011 Phosphatidylinositol-3-kinase and antiestrogen resistance in breast cancer. Journal of Clinical Oncology 29:4452–4461. (doi:10.1200/JCO.2010.34.4879)

Noh WC, Kim YH, Kim MS, Koh JS, Kim HA, Moon NM & Paik NS. 2008 Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Research and Treatment 110:477–483. (doi:10.1007/s10549-007-9746-x)

Pardo OE & Seckl MJ. 2013 S6K2: the neglected S6 kinase family member. Frontiers in Oncology 3:191. (doi:10.3389/fonc.2013.00191)
Park IH, Bachmann R, Shirazi H & Chen J 2002 Regulation of ribosomal S6 kinase 2 by mammalian target of rapamycin. Journal of Biological Chemistry 277 31423–31429. (doi:10.1074/jbc.M204080200)

Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Karlsson E, Waltersson MA, Nieh K, Holmlund B, Miura H, Pende M, Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Mestan J, Mueller M, Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J & Rozengurt E 2013 Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS ONE 8 e57289. (doi:10.1371/journal.pone.0057289)

Stidham R & Basu A 2011 S6 kinase 2 promotes breast cancer cell survival via Akt. Cancer Research 71 2590–2599. (doi:10.1158/0008-5472.CAN-10-3253)

Stål O, Borg A, Ferno M, Kalliström AC, Malmstrom P, Nordenskjöld B, South Sweden Breast Cancer Group & Southeast Sweden Breast Cancer Group 2000 ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Annals of Oncology 11 1545–1550.

Swedish Breast Cancer Cooperative Group 1996 Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Journal of the National Cancer Institute 88 1543–1549. (doi:10.1093/jnci/88.21.1543)

Tabenero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal I et al. 2008 Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. Journal of Clinical Oncology 26 1603–1610. (doi:10.1200/JCO.2007.14.5482)

Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J et al. 2004 Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 200–205. (doi:10.1038/nature03866)

Valovka T, Verdier F, Cramer R, Zhyvoloup A, Fenton T, Rebholz H, Wang ML, Gzhegotsky M, Lutsyk A, Matsuka G et al. 2003 Protein kinase C phosphorylates ribosomal protein S6 kinase 56 kinase III and regulates its subcellular localization. Molecular and Cellular Biology 23 852–863. (doi:10.1128/MCB.23.3.852-863.2003)

Wrang O, Nordenskjöld B & Gustafsson JA 1978 Cytosol estradiol receptor in human mammary carcinoma: an assay based on isoelectric focusing in polyacrylamide gel. Analytical Biochemistry 85 461–475. (doi:10.1016/0003-2697(78)90243-9)

Yamnik RL & Holz MK 2010 mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor α serine 167 phosphorylation. FASEB Journal 24 124–128. (doi:10.1096/fj.2009.11.041)

Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ & Holz MK 2009 S6 kinase 1 regulates estrogen receptor α in control of breast cancer cell proliferation. Journal of Biological Chemistry 284 6361–6369. (doi:10.1074/jbc.M807532200)

Received in final form 29 January 2015
Accepted 20 March 2015
Made available online as an Accepted Preprint 23 March 2015